BACKGROUND: Osteonecrosis (ON) is a disabling complication of chemotherapy, especially steroids in children and adolescents. There are few reports in the literature of non-surgical management of ON. Patients with chemotherapy related ON, treated with zoledronic acid (ZA) were analyzed for clinical and radiological outcome. METHODS: Retrospective chart review. Serial joint radiographs were performed to assess response and graded according to Association Research Circulation Osseous (ARCO) system. All patients were evaluated for bone turnover and bone mineral density (BMD) at set intervals. RESULTS: Twenty children with ON were treated with ZA for median duration of 13 months (range 5-25) with median number of doses being 6 (2, 8). Five (25%) patients were pain free at the end of treatment and had minimal joint destruction on X-ray (ARCO score II); 5 (25%) underwent arthroplasty due to severe joint destruction and pain limiting activity (ARCO score III/IV); 10 (50%) reported ongoing pain with activity, none on regular analgesia. BMD analysis showed increase in lumbosacral BMD after 1 year of treatment. Compared to patients with ON of the knees, majority of patients with ON of the hips had radiological progression. CONCLUSION: ZA was well tolerated and improved joint pain in the majority of patients. Despite treatment with ZA, most patients with ON of hips had progressive joint destruction requiring arthroplasty. Patients with ON of the knees appeared to have radiological stabilization. Novel treatment strategies should be considered to prevent this debilitating complication in survivors of childhood cancer.
BACKGROUND:Osteonecrosis (ON) is a disabling complication of chemotherapy, especially steroids in children and adolescents. There are few reports in the literature of non-surgical management of ON. Patients with chemotherapy related ON, treated with zoledronic acid (ZA) were analyzed for clinical and radiological outcome. METHODS: Retrospective chart review. Serial joint radiographs were performed to assess response and graded according to Association Research Circulation Osseous (ARCO) system. All patients were evaluated for bone turnover and bone mineral density (BMD) at set intervals. RESULTS: Twenty children with ON were treated with ZA for median duration of 13 months (range 5-25) with median number of doses being 6 (2, 8). Five (25%) patients were pain free at the end of treatment and had minimal joint destruction on X-ray (ARCO score II); 5 (25%) underwent arthroplasty due to severe joint destruction and pain limiting activity (ARCO score III/IV); 10 (50%) reported ongoing pain with activity, none on regular analgesia. BMD analysis showed increase in lumbosacral BMD after 1 year of treatment. Compared to patients with ON of the knees, majority of patients with ON of the hips had radiological progression. CONCLUSION:ZA was well tolerated and improved joint pain in the majority of patients. Despite treatment with ZA, most patients with ON of hips had progressive joint destruction requiring arthroplasty. Patients with ON of the knees appeared to have radiological stabilization. Novel treatment strategies should be considered to prevent this debilitating complication in survivors of childhood cancer.
Authors: Sobenna George; David R Weber; Paige Kaplan; Kelly Hummel; Heather M Monk; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2015-08-26 Impact factor: 5.958
Authors: Mariël L Te Winkel; Rob Pieters; Ernst-Jan D Wind; J H J M Gert Bessems; Marry M van den Heuvel-Eibrink Journal: Haematologica Date: 2014-03 Impact factor: 9.941
Authors: Shanaz M Daneshdoost; Jad M El Abiad; Kathy J Ruble; Lynne C Jones; Janet L Crane; Carol D Morris; Adam S Levin Journal: J Pediatr Hematol Oncol Date: 2021-04-01 Impact factor: 1.289
Authors: Laura J Janke; Jieun Kim; Monique A Payton; David A Jenkins; Xiangjun Cai; Emily R Finch; Yiwei Liu; Mary V Relling; Seth E Karol Journal: Pediatr Blood Cancer Date: 2021-06-14 Impact factor: 3.838